Business

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

Financial Post · October 9, 2026 at 6:35 p.m.

VANCOUVER, British Columbia -- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced an extension to its option agreement to license the National Research Council of Canada’s (NRC) proprietary nanobody-based CD22 binder for use in Chimeric Antigen Receptor (CAR) therapy.

ME Therapeutics will continue developing the CD22 nanobody as part of its in vivo CAR program.

The option to license the CD22 binder is now exercisable until February 10, 2027.

All other terms remain the same.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

More from Financial Post

Westport Rebrands as Aetherion™ Technologies, Focused on Accelerating Proven Solutions for Heavy-Duty Clean Transport

Cresco Labs to Report Third Quarter 2026 Financial Results on November 6, 2026

Transaction in Own Shares

Organigram Provides Update on Integration of Sanity Group and Unified Global Operating Model

More in Business

Westport Rebrands as Aetherion™ Technologies, Focused on Accelerating Proven Solutions for Heavy-Duty Clean Transport

Cresco Labs to Report Third Quarter 2026 Financial Results on November 6, 2026

Transaction in Own Shares

Organigram Provides Update on Integration of Sanity Group and Unified Global Operating Model

Moncler Re/Icons: Cher, JENNIE and Grace Jones Re/Define What It Means to Be a Pioneer

Venture Global Secures New Agreements to Support Expansion of Existing Grid-Independent Power Network